Surgery – Instruments – Light application
Reexamination Certificate
2005-08-30
2005-08-30
Farah, A. (Department: 3739)
Surgery
Instruments
Light application
C606S005000, C607S089000, C128S898000
Reexamination Certificate
active
06936043
ABSTRACT:
Age-related macular degeneration (AMD) results in the formation of new blood vessels in the eye. The walls of these vessels leak fluid, which causes scarring in the surrounding tissue, resulting in reduced vision or loss of vision. Photodynamic therapy (PDT) alone has been used to treat AMD, but many retreatments are needed, which cause further damage to the already diseased area. Laser treatment to coagulate the fluid actually causes additional new vessels to form. However, the inventive method of treating patients with both PDT and laser coagulation surprisingly either improved vision, or prevented further loss of vision. Moreover, the combined treatment eliminated the need for retreatment, and did not generate new vessel growth. Laser coagulation and PDT may be administered within the same treatment session or either may be administered first and the other may be administered within ninety days.
REFERENCES:
patent: 5633275 (1997-05-01), Mori et al.
patent: 5935942 (1999-08-01), Zeimer
patent: 6162242 (2000-12-01), Peyman
patent: 6524330 (2003-02-01), Khoobehi et al.
patent: 6607522 (2003-08-01), Hamblin et al.
patent: 2002/0165525 (2002-11-01), Nakamura
patent: 2003/0171320 (2003-09-01), Guyer
patent: 2004/0002694 (2004-01-01), Pawlowski et al.
The Choroidal Neovascularization Prevention Trail Group “Laser Treatment in Eyes with Large Drusen: Short-term Effects Seen in a Pilot randomized Clinical Trial,” Arch. Ophthalmol., Feb., 2001; 119: 198-207.
Exhibit A “The latest research on photodynamic therapy for macular degeneration,” American Federation for Aging Research, Apr. 3, 2003, www.infoaging.org/d-macu-6-r-photodynamic.html.
The Choroidal Neovascularization Prevention Trail Group “Laser Treatment in Eyes with Large Drusen: Short-term Effects See in a Pilot randomized Clinical Trial,” Arch. Ophthalmol., Feb., 2001; 119: 198-207.
Bressler, N.M.: Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration with Verteporfin: One-year Results of 2 Randomized Clinical Trials—TAP Report 1,Ophthlmol. 1999; 117: 1329-45.
Bressler, N.M.: Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: Two-year Results of 2 Randomized Clinical Trials—TAP Report 2,Ophthalmol. 2001; 119: 198-207.
The Choroidal Neovascularization Prevention Trial Research Group: Laser Treatment in Eyes with Large Drusen: Short-term Effects Seen in a Pilot Randomized Clinical Trial,Arch. Ophthalmol., Feb., 2001; 119: 198-207.
Verteporfin in Photodynamic Therapy Study Group: Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Two-year Results of a Randomized Clinical Trial Including Lesions with Occult with no Classic Choroidal Neovascularization—Verteporfin in Photodynamic Therapy Report 2,Am. Jour. of Ophthal., May, 2001; 131: 541-560.
Poster, “Combined Verteporfin Ocular Photodynamic Therapy with Macular Scatter Photocoagulation for Occult Subfoveal Neovascularization in ARMD”, Gholam Peyman, et al., Retina Congress, Sep. 28-Oct. 2, 2002.
Peyman, et al.,Verteporfin Ocular Photodynamic Therapy Combined with Macular Scatter Photocoagulation of Occult or Predominantly Occult Subfoveal Neovascularization in Age-Related Macular Degeneration: A Follow Up, Association for Research in Vision and Opthalmology (ARVO), Abstract, presented May 8, 2003 at the ARVO Conference, Poster Session Program No./Board No. 4999-B658.
Poster,Verteporfin Ocular Photodynamic Therapy Combined with Macular Scatter Photocoagulation of Occult or Predominantly Occult Subfoveal Neovascularization in Age-Related Macular Degeneration: A Follow Up, Peyman, et al., Association for Research in Vision and Ophthalmology (ARVO) Conference, May 4-9, 2003; presented May 8, 2003, Poster Session Program No./Board No. 4999-B658.
Farah A.
Minu LLC
Wood Herron & Evans L.L.P.
LandOfFree
Method to treat age-related macular degeneration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to treat age-related macular degeneration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to treat age-related macular degeneration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3480490